Amlodipine/atorvastatin: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 20:09, 28 August 2011 editBogBot (talk \| contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot ← Previous edit		Latest revision as of 06:06, 17 June 2024 edit undoWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,181 editsm script-assisted date audit and style fixes per MOS:NUM
(38 intermediate revisions by 26 users not shown)
Line 1:		Line 1:
			{{Short description\|Cholesterol and blood pressure medication}}
			{{Use dmy dates\|date=June 2024}}
			{{cs1 config \|name-list-style=vanc \|display-authors=6}}
	{{Drugbox		{{Drugbox
	\| verifiedrevid = ~~396294114~~		\| verifiedrevid = 424685654
	\| image = ~~Amlodipine~~.~~png~~		\| image = Atorvastatin.svg
	\| ~~image2~~ = ~~Lipitor.png~~		\| width = 250
			\| image2 = Amlodipine.svg
			\| width2 = 185

	<!--Combo data-->		<!--Combo data-->
Line 12:		Line 17:

	<!--Clinical data-->		<!--Clinical data-->
	\| tradename =		\| tradename = Caduet, Envacar, others
			\| Drugs.com = {{drugs.com\|ppa\|amlodipine-and-atorvastatin}}
⚫	\| ~~pregnancy_AU~~ = <!-- A / B1 / B2 / B3 / C / D ~~/ X~~ -->
	\| ~~pregnancy_US~~ = X		\| DailyMedID = Caduet
	\| ~~pregnancy_category~~ =		\| pregnancy_AU = D
			\| pregnancy_US = N
	\| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
			\| pregnancy_category = Contraindicated
⚫	\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
			\| legal_AU = S4
	\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
		⚫	\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
		⚫	\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
	\| legal_US = Rx-only		\| legal_US = Rx-only
	\| legal_status =		\| legal_status = Rx-only
	\| routes_of_administration = Oral		\| routes_of_administration = ]

	<!--Identifiers-->		<!--Identifiers-->
	\| CAS_number =		\| CAS_number = 858659-02-6
	\| ATC_prefix = C10		\| ATC_prefix = C10
	\| ATC_suffix = BX03		\| ATC_suffix = BX03
Line 31:		Line 38:
	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}		\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| ChemSpiderID = 7987512		\| ChemSpiderID = 7987512
			\| KEGG = D08488

	<!--Chemical data-->		<!--Chemical data-->
	\| smiles = Clc1ccccc1C2C(\C(=O)OC)=C(/N\C(=C2\C(=O)OCC)COCCN)C.O=C(O)C(O)C(O)CCn2c(c(c(c2c1ccc(F)cc1)c3ccccc3)C(=O)Nc4ccccc4)C(C)C
	\| InChI = 1/C33H35FN2O5.C20H25ClN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);5-8,17,23H,4,9-11,22H2,1-3H3/t26-,27-;/m1./s1
	\| InChIKey = PEAJXAZCGDWDGS-CNZCJKERBU
	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChI = 1S/C33H35FN2O5.C20H25ClN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);5-8,17,23H,4,9-11,22H2,1-3H3/t26-,27-;/m1./s1
	\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChIKey = PEAJXAZCGDWDGS-CNZCJKERSA-N
	}}		}}

	The drug combination '''atorvastatin/amlodipine''' (trade names '''Caduet''' in the ] and ], and '''Envacar''' elsewhere) is a medication approved by the ] (FDA) for the treatment of ] and ]. It is a ] drug containing the ] ] and the ] ]. It is being marketed by the ] ].<ref>{{cite web\|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm202933.htm\|format=PDF\|title=CADUET (amlodipine besylate/atorvastatin calcium) Tablets\|month=February \| year=2010\|work=NDA 21-540/S-009\|publisher=]\|accessdate=2010-09-25}}</ref>
			'''Amlodipine/atorvastatin''', sold under the brand name '''Caduet''' among others, is a ] medication for the treatment of ] and ]. It contains a ] and a ].<ref name="Curran 2010 pp. 191–213">{{cite journal \| last=Curran \| first=Monique P. \| title=Amlodipine/Atorvastatin \| journal=Drugs \| publisher=]\| volume=70 \| issue=2 \| year=2010 \| issn=0012-6667 \| doi=10.2165/11204420-000000000-00000 \| pages=191–213\| pmid=20108992 \| s2cid=209144335 }}</ref><ref>{{cite journal \| vauthors = Devabhaktuni M, Bangalore S \| title = Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives \| journal = Vascular Health and Risk Management \| volume = 5 \| issue = 1 \| pages = 377–87 \| date = 2009 \| pmid = 19475775 \| pmc = 2686256 \| doi = 10.2147/vhrm.s3339 \| doi-access = free }}</ref>

			== Society and culture ==
			=== Brand names ===
			Amlodipine/atorvastatin is marketed under the brand name Caduet in the United States, Australia, and Russia, and Envacar in the Philippines.<ref>{{cite web \|url=https://www.drugs.com/international/caduet.html \|url-status=dead \|archive-url=https://web.archive.org/web/20140619222725/http://www.drugs.com/international/caduet.html \|archive-date=19 June 2014 \|title=Caduet - Drugs.com}}</ref><ref>{{cite web \|url=https://www.drugs.com/international/envacar.html \|url-status=dead \|archive-url=https://web.archive.org/web/20140620180116/http://www.drugs.com/international/envacar.html \|archive-date=20 June 2014 \|title=Envacar - Drugs.com}}</ref>

			In some countries Caduet is marketed by ] after Upjohn was spun off from Pfizer.<ref>{{cite web \| title=Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan \| publisher=Pfizer \| via=Business Wire \| date=16 November 2020 \| url=https://www.businesswire.com/news/home/20201116005378/en/ \| access-date=17 June 2024}}</ref><ref>{{cite web \| title=Caduet \| website=Pfizer \| url=https://www.pfizer.com/products/product-detail/caduet \| access-date=17 June 2024}}</ref><ref>{{cite web \| title=Brands \| website=Viatris \| date=16 November 2020 \| url=https://www.viatris.com/en/products/brands \| access-date=17 June 2024}}</ref>

	== References ==		== References ==
	{{reflist}}		{{reflist}}

			{{Lipid modifying agents}}
	== External links ==
			{{Portal bar\|Medicine}}
	* (caduet.com)

			{{DEFAULTSORT:Amlodipine Atorvastatin}}
	]
	]		]
	]		]

Latest revision as of 06:06, 17 June 2024

Cholesterol and blood pressure medication

Pharmaceutical compound

Amlodipine/atorvastatin
Combination of


Amlodipine	Calcium channel blocker
Atorvastatin	Statin
Clinical data
Trade names	Caduet, Envacar, others
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Caduet
Pregnancy category	AU: D Contraindicated
Routes of administration	By mouth
ATC code	C10BX03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) US: ℞-only In general: ℞ (Prescription only)
Identifiers
CAS Number	858659-02-6
PubChem CID	9811759
ChemSpider	7987512
KEGG	D08488
CompTox Dashboard (EPA)	DTXSID101027010
(verify)

Amlodipine/atorvastatin, sold under the brand name Caduet among others, is a fixed-dose combination medication for the treatment of high cholesterol and high blood pressure. It contains a statin and a calcium channel blocker.

Society and culture

Brand names

Amlodipine/atorvastatin is marketed under the brand name Caduet in the United States, Australia, and Russia, and Envacar in the Philippines.

In some countries Caduet is marketed by Viatris after Upjohn was spun off from Pfizer.

References

Curran MP (2010). "Amlodipine/Atorvastatin". Drugs. 70 (2). Springer Science+Business Media: 191–213. doi:10.2165/11204420-000000000-00000. ISSN 0012-6667. PMID 20108992. S2CID 209144335.
Devabhaktuni M, Bangalore S (2009). "Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives". Vascular Health and Risk Management. 5 (1): 377–87. doi:10.2147/vhrm.s3339. PMC 2686256. PMID 19475775.
"Caduet - Drugs.com". Archived from the original on 19 June 2014.
"Envacar - Drugs.com". Archived from the original on 20 June 2014.
"Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
"Caduet". Pfizer. Retrieved 17 June 2024.
"Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

Lipid-lowering agents (C10)

GI tract

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe Hyzetimibe SCH-48461
Bile acid sequestrants/resins (LDL)	Colesevelam Colestilan Colestipol Colestyramine Colextran Soluble fiber such as psyllium and glucomannan

Liver

Statins (HMG-CoA reductase, LDL)	Atorvastatin Cerivastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin
Niacin and derivatives (HDL and LDL)	Acipimox Aluminium nicotinate Niacin Niceritrol Nicofuranose Nicotinyl alcohol
MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide
ATP citrate lyase inhibitors (LDL)	Bempedoic acid
Thyromimetics (VLDL)	Dextrothyroxine Resmetirom

Blood vessels

PPAR agonists (LDL)

Fibrates	Aluminium clofibrate Bezafibrate Choline fenofibrate Ciprofibrate Clinofibrate Clofibrate Clofibride Etofibrate Fenofibrate Gemfibrozil Nafenopin Pemafibrate Ronifibrate Simfibrate
Others	GW501516

CETP inhibitors (HDL)

PCSK9 inhibitors (LDL)

ANGPTL3 inhibitors (LDL/HDL)

Evinacumab

Combinations

Other

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Portal:

Medicine

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: